Purchase Order 75F40122P00055
Award Date 5/17/22
Potential Completion Date 11/29/23
Potential Value $995K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Storrs, CT 06269, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Nanopharm LIMITED was awarded a definitive cost-no-fee contract valued at one hundred twenty-nine thousand four hundred sixty-nine dollars by the Department of Health and Human Services Food and Drug Administration to support the agency's PMQWP 202 broad agency announcement. Under the contract, Nanopharm will perform work investigating orthogonal analytical approaches to demonstrate bioequivalence of nasal suspension formulations. The place of performance will be Silver Spring, Maryland. No...
- The University of Connecticut has been awarded a definitive contract by the Department of Health and Human Services Food and Drug Administration to continue processing liposomal nanoparticles as reference materials for drug product development. With a potential value of $349,364, this time and materials contract does not have a set-aside designation and is to be completed by May 31, 2023. As the prime contractor, the University will utilize its expertise in nanotechnology and materials...
- This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...
- This is a $4,999,953.00 firm fixed price definitive contract awarded by the Food and Drug Administration (FDA) to the National Institute for Pharmaceutical Technology & Education Inc. (Nipte), a non-profit organization. The contract was awarded under the FDA's Broad Agency Announcement mechanism to support research and development on a "model-based systems engineering approach to end-to-end pharmaceutical manufacturing of liquid" products. This contract is not associated with a...
- The Department of Health and Human Services Food and Drug Administration awarded a $25,025 firm fixed price purchase order to Nanocomposix, LLC for the production of amino-functionalized silica nanoparticles for in vivo analysis of blood-brain barrier safety and integrity. Performance will take place in Silver Spring, Maryland by September 15, 2023. No set-aside designation was applied to this contract for Nanocomposix to deliver amino-functionalized silica nanoparticles to the FDA, presumably...
- The Food and Drug Administration (FDA) has awarded a $183,300 firm fixed price purchase order to Particle Metrix Inc., a woman-owned small disadvantaged business, for a Colocalized Nanoparticle Tracking Analysis (C-NTA) System. This system will be used to support laboratory projects by the FDA's Center for Biologics Evaluation and Research (CBER), Office of Blood Research and Review (OBRR), Division of Blood Components and Devices (DBCD). The contract has a completion date of September 25,...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $111,894.56 firm fixed price purchase order contract to Precision Nanosystems US Inc., a for-profit organization. The contract is for the provision of a NanoAssemblr Ignite Automated Microfluidics Instrument, with a performance period ending on October 30, 2022. Precision Nanosystems has previously provided similar microfluidics and nanoparticle...
- This federal contract award, with ID 75F40122C00192, was issued by the Food and Drug Administration (FDA) to the National Institute for Pharmaceutical Technology & Education Inc. (Nipte), a non-profit organization. The $3,000,000.00 cost-no-fee contract is for continuous drug substance manufacturing from biomass-derived building blocks, in support of the FDA's effort to advance regulatory science. This contract was awarded under the FDA's Broad Agency Announcement mechanism, which solicits...
- The U.S. Food and Drug Administration (FDA) awarded a $4,400,000.00 Cost Plus Fixed Fee contract to Continuus Pharmaceuticals, Inc. to support the "ADVANCEMENT OF INTEGRATED CONTINUOUS MANUFACTURING (ICM) UNIT OPERATIONS." This definitive contract does not have a set-aside designation and is scheduled to be completed by September 29, 2019. The contract is part of the FDA's efforts to advance integrated continuous manufacturing unit operations, which is a major program focus area for...
- The U.S. Food and Drug Administration (FDA) awarded a $189,328.00 firm fixed-price purchase order to Govage, Inc., a small, minority-owned business based in Hazelwood, Missouri. The contract is for the procurement of Nanion consumables to perform ion channel pharmacology experiments using the SyncroPatch 384 automated patch clamp system. This contract was originally solicited as a total small business set-aside under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing). The...